Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer
- 11 October 2023
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 261, 115868
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Osimertinib: First Global ApprovalDrugs, 2016
- Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealedJournal of Structural Biology, 2015
- Entrectinib: a potent new TRK, ROS1, and ALK inhibitorExpert Opinion on Investigational Drugs, 2015
- Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2015
- Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancerCurrent Opinion in Oncology, 2015
- Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant MutationsJournal of Medicinal Chemistry, 2014
- Propanephosphonic Acid Anhydride (T3P®) - A Benign Reagent for Diverse Applications Inclusive of Large-Scale SynthesisSynthesis, 2013
- Dacomitinib, a new therapy for the treatment of non-small cell lung cancerExpert Opinion on Pharmacotherapy, 2013
- Administration of a Tropomyosin Receptor Kinase Inhibitor Attenuates Sarcoma-Induced Nerve Sprouting, Neuroma Formation and Bone Cancer PainMolecular Pain, 2010
- 2,5-Dimethylpyrrole Protection Facilitates Copper(I)-Mediated Methoxylations of Aryl Iodides in the Presence of AnilinesSynthesis, 1998